Hereditary Angioedema
Welcome,         Profile    Billing    Logout  
 24 Companies   6 Products   6 Products   5 Mechanisms of Action   48 Trials   3169 News 
80 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hereditary Angioedema
NCT06690047: Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)

Completed
4
5
US
Ruconest
Bernstein Clinical Research Center
Hereditary Angioedema
04/22
04/22
NCT06806657: Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

Not yet recruiting
4
30
US
Garadacimab, CSL312 and Factor XIIa inhibitor monoclonal antibody
CSL Behring
Hereditary Angioedema
06/26
06/26
ChiCTR2500098307: A Single-center Retrospective Study on the Clinical Characteristics of Patients with Hereditary Angioedema and the Therapeutic Effect of Lanadelumab

Recruiting
4
20
 
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Hereditary Angioedema
 
 
2004-004282-15: A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema

Ongoing
3
Europe
Recombinant human C1 inhibitor, rhC1INH, Concentrate for solution for infusion
PHARMING TECHNOLOGIES B.V.
hereditary angioedema (HAE) treatment
 
 
2010-019670-32: Pharmacokinetics and Safety of Human Pasteurised C1-Inhibitor Concentrate (Berinert/CE1145) in Subjects with Congenital C1-INH Deficiency. Studio della farmacocinetica e della sicurezza del C1-Inibitore concentrato pasteurizzato umano (Berinert/CE1145) in soggetti con deficienza congenita di C1-INH.

Ongoing
3
3
Europe
Powder and solvent for solution for injection, BERINERT*IV FL 500U+FL 10ML
AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE), CSL Behring
Hereditary Angioedema (HAE) angioedema ereditario, Hereditary Angioedema (HAE) angioedema ereditario, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
KONFIDENT, NCT05259917 / 2021-001226-21: A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Completed
3
136
Europe, Canada, Japan, US, RoW
Placebo, KVD900 600 mg, KVD900 300 mg
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
12/23
12/23
OASIS-HAE, NCT05139810 / 2021-002571-19: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Completed
3
91
Europe, Canada, US, RoW
Donidalorsen, Placebo
Ionis Pharmaceuticals, Inc.
Hereditary Angioedema
11/23
11/23
RAPIDe-3, NCT06343779: Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Recruiting
3
120
Europe, Canada, Japan, US, RoW
Deucrictibant, Placebo
Pharvaris Netherlands B.V.
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency
03/26
03/26
2023-001105-31: A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Not yet recruiting
3
20
RoW
TAKHZYRO, TAK-743, SHP643, DX-2930, Solution for injection in vial, Takhzyro
Takeda, Takeda
Hereditary Angioedema (HAE), Angioedema is a long-term and life-threatening disease. It manifests clinically as unpredictable, intermittent attacks of edema of the face, larynx, gastrointestinal tract, limbs and/or genitalia., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
CONE-02, NCT06361537: Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Recruiting
3
124
Europe, US, RoW
OCTA-C1-INH, Placebo
Octapharma
Acute Hereditary Angio Edema
12/26
12/26
NCT05460325 / 2023-001105-31: A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Completed
3
20
RoW
Lanadelumab, SHP643, TAKHZYRO, TAK-743, DX-2930, Lanadelumab Injection
Takeda, Takeda
Hereditary Angioedema (HAE)
11/23
11/23
KONFIDENT-KID, NCT06467084: Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) with HAE Type I or II

Recruiting
3
24
Europe, Canada, Japan, US, RoW
KVD900 75 mg, KVD900 150 mg, KVD900 300 mg
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
08/27
08/27
CHAPTER-3, NCT06669754: Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Recruiting
3
81
Europe, US, RoW
Deucrictibant, Placebo
Pharvaris Netherlands B.V.
Hereditary Angioedema (HAE)
08/26
08/26
HAELO, NCT06634420: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

Recruiting
3
60
Europe, Canada, US, RoW
NTLA-2002, Normal Saline IV Administration
Intellia Therapeutics
Hereditary Angioedema
04/26
09/27
CHAPTER-4, NCT06679881: Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Recruiting
3
130
Europe, RoW
Deucrictibant
Pharvaris Netherlands B.V.
Hereditary Angioedema (HAE)
12/28
12/28
ALPHA-ORBIT, NCT06842823: A Study of Navenibart in Participants with Hereditary Angioedema

Recruiting
3
145
US
navenibart, STAR-0215, Placebo
Astria Therapeutics, Inc.
Hereditary Angioedema (HAE)
03/27
09/27
APeX-P, NCT05453968 / 2021-005932-50: Berotralstat Treatment in Children With Hereditary Angioedema

Active, not recruiting
3
29
Europe, Canada, RoW
Berotralstat, BCX7353, Orladeyo®
BioCryst Pharmaceuticals
Hereditary Angioedema, Pediatric
09/24
02/27
NCT04739059 / 2020-003918-12: Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Active, not recruiting
3
171
Europe, Canada, Japan, US, RoW
CSL312, Factor XIIa inhibitor monoclonal antibody, garadacimab
CSL Behring
Hereditary Angioedema
11/25
11/25
NCT05511922: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Recruiting
3
12
Europe, Canada, Japan, US, RoW
KVD900 600 mg, Drug: KVD900 300 mg
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
06/26
06/26
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Active, not recruiting
3
20
Europe, Canada, US, RoW
CSL312, Garadacimab
CSL Behring
Hereditary Angioedema (HAE)
11/26
11/26
KONFIDENT-S, NCT05505916 / 2021-001176-42: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Active, not recruiting
3
145
Europe, Canada, Japan, US, RoW
KVD900 600 mg, KVD900 300 mg
KalVista Pharmaceuticals, Ltd., KalVista Pharmaceuticals Ltd
Hereditary Angioedema
06/26
06/26
APeX-A, NCT04933721 / 2020-004230-37: Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

Active, not recruiting
3
110
Europe, RoW
berotralstat, Orladeyo
BioCryst Pharmaceuticals
Hereditary Angioedema, HAE
08/26
08/26
NCT05392114 / 2022-000757-93: A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

Recruiting
3
144
Europe, Canada, US, RoW
Donidalorsen, ISIS 721744, IONIS-PKK-LRx
Ionis Pharmaceuticals, Inc.
Hereditary Angioedema
12/26
03/27
2021-006906-58: An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in patients with hereditary angioedema Estudio de extensión de fase II/III para probar la seguridad de la administración a largo plazo de PHA-022121 oral para el tratamiento agudo de los ataques de angioedema en pacientes con angioedema hereditario.

Ongoing
2/3
72
Europe
PHVS416, PHA-022121, Capsule, soft
Pharvaris Netherlands BV, Pharvaris Netherlands BV
Hereditary angioedema attacks caused by Type 1 and 2 C1-Inhibitor Deficiency Ataques de angioedema hereditario causados por la deficiencia del inhibidor C1 tipo 1 y 2, Hereditary angioedema (HAE) is a disorder that results in recurrent attacks of severe swelling El angioedema hereditario (AEH) es un trastorno que provoca ataques recurrentes de inflamación grave, Body processes [G] - Immune system processes [G12]
 
 
RAPIDe-2, NCT05396105: Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema

Enrolling by invitation
2/3
140
Europe, Canada, US, RoW
deucrictibant selected dose, PHVS416, PHA121, PHA-022121
Pharvaris Netherlands B.V.
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema with C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency
06/27
06/27
2015-003923-74: A placebo controlled trial of of three doses of BCX7353 to evaluate the safety and efficacy in the prevention of attacks in patients with HAE

Ongoing
2
24
Europe
BC7353, BCX7353, Capsule, hard
BioCryst Pharmaceuticals Inc, BioCryst Pharmaceutical Inc
Hereditary Angioedema, Hereditary Angioedema, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2018-004136-30: Lanadelumab tested in patients suffering from hereditary angioedema with normal C1-Inhibitor.

Not yet recruiting
2
5
Europe
Lanadelumab, Solution for injection in pre-filled syringe, Takzhyro (Lanadelumab)
Charité - Universitätsmedizin Berlin Klinik für Dermatologie und Allergologie, Shire International GmbH
Lanadelumab in patients with Hereditary angioedema Hereditäres Angioödem, Hereditary angioedema with normal C1-INH is a rare genetic disease which is characterized by self-limiting episodes of marked edema involving the skin, gastrointestinal tract and other organs., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2020-000197-14: An Extension Study of IONIS-PKK-LRx in Participants With Hereditary Angioedema

Not yet recruiting
2
24
Europe
ISIS 721744, Solution for injection
Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc.
Hereditary Angioedema, Genetic disease characterized by the occurrence of transitory and recurrent subcutaneous and/or submucosal edemas resulting in swelling and/or abdominal pain, Body processes [G] - Genetic Phenomena [G05]
 
 
2019-001693-28: Single-arm pharmacokinetic phase 2a study of a single dose intravenous human plasma-derived C1-INH involving 20 HAE type I or type II patients, aged 18 years or older

Not yet recruiting
2
20
Europe
C1 Esterase Inhibitor Human, OCTA-C1-INH, Powder for solution for injection
Octapharma Pharmazeutika Produktionsges.m.b.H., Octapharma Pharmazeutika Produktionsges.m.b.H.
Hereditary angioedema type I and type II, Hereditary angioedema (HAE), Body processes [G] - Immune system processes [G12]
 
 
2018-000605-24: A study to investigate CSL312 in subjects with hereditary angioedema (HAE)

Not yet recruiting
2
50
Europe
Factor XIIa antagonist monoclonal antibody, CSL312, Solution for injection
CSL Behring LLC, CSL Behring LLC
Hereditary angioedema, Hereditary angioedema (HAE) is a condition characterized by painful, recurring attacks of swelling in parts of the body including the face, throat, hands, feet, abdomen., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
2021-000227-13: A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for prophylaxis of angioedema attacks in patients with hereditary angioedema (HAE).

Not yet recruiting
2
30
Europe, RoW
PHVS416, PHA-022121, Capsule, soft
Pharvaris Netherlands BV, Pharvaris Netherlands B.V., Pharvaris Netherlands BV
Hereditary angioedema due to C1-Inhibitor Deficiency (Type I or Type II), Hereditary angioedema (HAE) is a disorder that results in recurrent attacks of severe swelling., Body processes [G] - Immune system processes [G12]
 
 
RAPIDe-1, NCT04618211 / 2020-003445-11: Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

Completed
2
74
Europe, Canada, US, RoW
Deucrictibant, PHA-022121, PHA121, PHVS416, Placebo
Pharvaris Netherlands B.V.
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
09/22
03/23
2021-000136-59: A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.

Not yet recruiting
2
48
Europe, RoW
KVD824 300 mg Modified Release Tablets, [N/A], Modified-release tablet
Kalvista Pharmaceuticals Ltd, KalVista Pharmaceuticals Ltd, Kalvista Pharmaceuticals Ltd
Hereditary Angioedema Type I or II, Hereditary Angioedema is a genetic condition characterised by swelling of tissues. These swellings can occur on any part of the body., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2022-003168-25: Prophylactic treatment with PHA-022121 in patients with acquired angioedema Onderhoudsbehandeling met PHA-022121 voor patiënten met verworven angio-oedeem

Ongoing
2
5
Europe
PHA-022121, Film-coated tablet
Academisch Medisch Centrum, Pharvaris
Acquired angioedema due to C1-inhibitor deficiency Verworven angio-oedeem op basis van een C1-esterase remmer deficiëntie, Acquired angioedema due to C1-inhibitor deficiency Verworven angio-oedeem op basis van een C1-esterase remmer deficiëntie, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2021-000720-36: Acute treatment and prophylaxis for acquired angioedema Aanvals- en onderhoudsbehandeling voor verworven angio-oedeem

Not yet recruiting
2
3
Europe
PHA-022121, Capsule, soft
Academisch Medisch Centrum, Pharvaris
Acquired angioedema due to C1-inhibitor deficiency Verworven angio-oedeem op basis van C1-esterase remmer deficiëntie, Acquired angioedema due to C1-inhibitor deficiency Verworven angio-oedeem op basis van C1-esterase remmer deficiëntie, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
HAE CHAPTER-1, NCT05047185 / 2021-000227-13: Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

Active, not recruiting
2
34
Europe, Canada, US
Deucrictibant low dose, Deucrictibant high dose, Placebo
Pharvaris Netherlands B.V., Pharvaris Netherlands BV
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
06/25
09/25
HAE, NCT06846398: A Phase 2 in Adult Subjects With Hereditary Angioedema

Not yet recruiting
2
24
Europe, US, RoW
BW-20805
Shanghai Argo Biopharmaceutical Co., Ltd.
Hereditary Angioedema (HAE)
06/26
03/28
NCT04307381 / 2020-000197-14: An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

Completed
2
20
Europe, US
Donidalorsen, ISIS 721744, IONIS-PKK-LRx
Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc.
Hereditary Angioedema
01/25
01/25
NCT06007677: A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

Recruiting
2
56
Europe, Canada, US, RoW
STAR-0215
Astria Therapeutics, Inc.
Hereditary Angioedema
03/31
03/31
2021-001693-33: A Study to Evaluate NTLA-2002 in adults with Hereditary Angioedema (HAE)

Not yet recruiting
1/2
55
Europe
NTLA-2002, NTLA-2002, Solution for infusion
Intellia Therapeutics, Inc., Intellia Therapeutics, Inc.
Hereditary Angioedema, Hereditary Angioedema is a genetic condition characterised by swelling of tissues. These swellings can occur on any part of the body., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
2021-003603-18: A Phase 1/2 Study to evaluate the Safety, Tolerability and Efficacy of BMN 331 Gene Therapy in Subjects with Hereditary Angioedema (HAE) Un estudio de fase 1/2 para evaluar la seguridad, tolerabilidad y eficacia de la terapia génica BMN 331 en sujetos con angioedema hereditario (AEH)

Not yet recruiting
1/2
34
Europe
BMN 331, Solution for infusion
BioMarin Pharmaceutical Inc., BioMarin Pharmaceutical Inc.
Hereditary Angioedema (HAE) Angioedema hereditario (AEH), Hereditary Angioedema (HAE) Angioedema hereditario (AEH), Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NTLA-2002, NCT05120830 / 2021-001693-33: in Adults With Hereditary Angioedema (HAE)

Active, not recruiting
1/2
37
Europe, RoW
Biological NTLA-2002, Normal Saline IV Administration
Intellia Therapeutics, Intellia Therapeutics, Inc.
Hereditary Angioedema
04/24
03/26
ALPHA-STAR, NCT05695248: A Study of STAR-0215 in Participants With Hereditary Angioedema

Active, not recruiting
1/2
28
Europe, Canada, US, RoW
STAR-0215
Astria Therapeutics, Inc.
Hereditary Angioedema
09/25
09/25
HAErmony-1, NCT05121376 / 2021-003603-18: A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

Active, not recruiting
1/2
44
Europe, US, RoW
Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331, Dose 4 of BMN 331, Dose 5 of BMN 331, Dose 6 of BMN 331, Dose 7 of BMN 331
BioMarin Pharmaceutical, BioMarin Pharmaceutical Inc.
Hereditary Angioedema, HAE
11/28
11/28
ACTRN12623000689673: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BW-20805 in Healthy Subjects

Recruiting
1
32
 
Argo Biopharma Australia Pty Ltd, Argo Biopharma Australia Pty Ltd
Hereditary angioedema
 
 
NCT05477160: A Study of STAR-0215 in Healthy Adult Participants

Completed
1
41
US
STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV)
Astria Therapeutics, Inc.
Hereditary Angioedema
11/23
11/23
NCT05691361: Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Recruiting
1
53
RoW
ADX-324, siRNA, Placebo, Saline
ADARx Pharmaceuticals, Inc., Avance Clinical Pty Ltd.
Hereditary Angioedema
07/25
01/26
ACTRN12623000736640: An open-label, multiple dose study to compare the single-dose and steady-state pharmacokinetics of a 40 mg PHA-022121 extended-release (XR) tablet administered once daily between healthy Japanese, Chinese, and Caucasian volunteers.

Completed
1
36
 
Pharvaris Netherlands B.V., Pharvaris Netherlands B.V.
Hereditary Angioedema (HAE)
 
 
NCT06415448: Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema

Available
N/A
NA
Donidalorsen, IONIS PKK-LRx, ISIS 721744
Ionis Pharmaceuticals, Inc.
Hereditary Angioedema
 
 
NCT06628713: Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat

Available
N/A
NA
Sebetralstat, KVD900
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
 
 
NCT03828279: Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and II

Recruiting
N/A
220
Europe
functional and antigenic C1 inhibitor, genetic analysis
HAE Global Registry Foundation
Hereditary Angioedema Type I and II
12/19
12/23
NCT01397864: C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

Completed
N/A
181
Europe, RoW
rhC1INH or pdC1INH, Ruconest
Pharming Technologies B.V.
Hereditary Angioedema
10/24
12/24
BESQAOH, NCT04888650: Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema

Completed
N/A
314
Europe
questionnaire
University Hospital, Grenoble
Hereditary Angioedema
01/22
01/22
EMPOWER, NCT03845400: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

Completed
N/A
168
Canada, US
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
10/22
10/22
Angiocoag, NCT02892682: The Role of the Coagulation Pathways in Recurrent Angioedema

Terminated
N/A
96
Europe
BLOOD TEST
University Hospital, Montpellier
Chronic Spotaneous Urticaria, Idiopathic Non Histaminergic Angioderma, Hereditary Angioedema With C1 Inhibitor Deficiency
05/23
05/23
FROSEN, NCT06414252: Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients

Completed
N/A
40
Europe
Istituti Clinici Scientifici Maugeri SpA
Hereditary Angioedema
03/24
03/24
ANS-HAE, NCT06408805: Autonomic Nervous System Profile in Hereditary Angioedema

Completed
N/A
60
Europe
Istituti Clinici Scientifici Maugeri SpA
Hereditary Angioedema
03/24
03/24
NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

No Longer Available
N/A
Europe, Canada, US
Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE), Angioedema
 
 
PRADA, NCT05776784: Status of Dental Care Practices in Patients With Hereditary Angioedema

Recruiting
N/A
800
Europe
dental procedure
University Hospital, Grenoble
Angio Edema Hereditary
07/23
12/23
TAK-743-4008, NCT04955964: A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

Completed
N/A
48
RoW
Takeda
Angioedemas, Hereditary
08/23
08/23
NCT05489640: A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home

Completed
N/A
85
Europe
No Intervention
Takeda
Hereditary Angioedema (HAE)
07/24
07/24
PROSPECT, NCT05578417: A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada

Completed
N/A
60
Canada
No Intervention
Takeda
Hereditary Angioedema (HAE), Angioedema
03/24
06/24
NCT06210698: Angioedema Biomarker Research Study

Not yet recruiting
N/A
600
NA
Venipuncture
Foundation For Rare Disease Research, Institute for Asthma & Allergy, Virant Diagnostics, Inc., MedBio Reference Laboratories, Inc.
Angioedema, Angioedemas, Hereditary, Urticaria, Mastocytosis, ACE Inhibitor-Induced Angioedema, C1 Inhibitor Deficiency, Systemic Mastocytoses, Indolent Systemic Mastocytosis
02/26
02/26
NCT04057131: FIRAZYR General Drug Use-Results Survey (Japan)

Completed
N/A
179
Japan
Firazyr, Icatibant acetate
Shire, Takeda
Hereditary Angioedema (HAE)
07/24
07/24
ITL-2002-CL-999, NCT06262399: Long-Term Follow-Up (LTFU) of Subjects Treated with NTLA 2002

Enrolling by invitation
N/A
100
Europe, RoW
Intellia Therapeutics
Hereditary Angioedema
04/40
04/40
NCT06573723: Institutional Registry of Rare Diseases

Recruiting
N/A
380
RoW
Hospital Italiano de Buenos Aires
Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, Cushing Syndrome
12/34
12/34
NCT06346899: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

Recruiting
N/A
130
RoW
No intervention
Takeda
Hereditary Angioedema (HAE)
08/25
08/25
ENABLE, NCT04130191: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

Completed
N/A
140
Europe, RoW
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
09/24
09/24
SPEAKUP, NCT06587464: A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People

Completed
N/A
19
RoW
No Intervention
Takeda
Hereditary Angioedema (HAE)
12/24
12/24
HAE-SAFE, NCT06811467: Suicide Ideation in Hereditary Angioedema

Not yet recruiting
N/A
100
NA
Ivan Cherrez Ojeda
Hereditary Angioedema (HAE), Suicidal Ideation, Cardiovascular Risk
08/25
09/25
ECRINS, NCT06806618: HAE Burden and Crisis Management

Recruiting
N/A
300
Europe
University Hospital, Grenoble
Hereditary Angioedema (HAE)
04/25
04/25
NCT05509569: A Survey of Icatibant in Pediatric Participants with Hereditary Angioedema

Active, not recruiting
N/A
32
RoW
Icatibant, FIRAZYR Subcutaneous Injection 30mg Syringe
Takeda
Hereditary Angioedema (HAE)
10/25
10/25
NCT05469789: A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)

Active, not recruiting
N/A
50
Europe
No Intervention
Takeda
Hereditary Angioedema (HAE)
12/26
12/26
ChiCTR2500099926: Phase I clinical study on the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of recombinant human C1 esterase inhibitor for injection in patients with hereditary angioedema

Not yet recruiting
N/A
18
 
Complete intravenous injection of 25 IU/kg within 2 minutes; Complete intravenous injection of 50 IU/kg within 5 minutes; Complete intravenous injection of 100 IU/kg within 10 minutes
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Chengdu Institute of Biological Products Co., Ltd, Self raised by enterprises
Hereditary angioedema
 
 
CHOPIN, NCT05147181: A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

Active, not recruiting
N/A
48
Europe
Takeda
Hereditary Angioedema (HAE)
03/26
03/26
GENOMAEH_01, NCT05833620: Identification and Characterization of Genetic Variants in Hereditary Angioedema

Not yet recruiting
N/A
200
Europe
Hospital Universitari Vall d'Hebron Research Institute, Hospital Universitario La Paz
Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
03/26
03/27
NCT05397431: A Survey of Lanadelumab in Participants with Hereditary Angioedema

Recruiting
N/A
100
Japan
Lanadelumab, SHP643 (TAK-743), TAKHZYRO
Takeda
Hereditary Angioedema (HAE)
01/26
01/26
NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Completed
N/A
1761
Europe, RoW
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
05/24
05/24
NAREG, NCT05904301: Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases

Recruiting
N/A
800
RoW
Usual medical management of patients, additional blood and stool samples for biobanking
Santé Arménie French-Armenian Research Center
Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis, Takayasu Arteritis, Giant Cell Arteritis, Sjogren's Syndrome, Rheumatoid Arthritis, Hereditary and Acquired Angioedema, Primary Antiphospholipid Syndrome, Celiac Disease
06/28
06/28
ACTRN12621000473864: The influence of stress and lifestyle in hereditary angioedema

Completed
N/A
32
 
University of Auckland, Auckland City Hospital
Hereditary angioedema
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hereditary Angioedema
NCT06690047: Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)

Completed
4
5
US
Ruconest
Bernstein Clinical Research Center
Hereditary Angioedema
04/22
04/22
NCT06806657: Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

Not yet recruiting
4
30
US
Garadacimab, CSL312 and Factor XIIa inhibitor monoclonal antibody
CSL Behring
Hereditary Angioedema
06/26
06/26
ChiCTR2500098307: A Single-center Retrospective Study on the Clinical Characteristics of Patients with Hereditary Angioedema and the Therapeutic Effect of Lanadelumab

Recruiting
4
20
 
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Hereditary Angioedema
 
 
2004-004282-15: A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema

Ongoing
3
Europe
Recombinant human C1 inhibitor, rhC1INH, Concentrate for solution for infusion
PHARMING TECHNOLOGIES B.V.
hereditary angioedema (HAE) treatment
 
 
2010-019670-32: Pharmacokinetics and Safety of Human Pasteurised C1-Inhibitor Concentrate (Berinert/CE1145) in Subjects with Congenital C1-INH Deficiency. Studio della farmacocinetica e della sicurezza del C1-Inibitore concentrato pasteurizzato umano (Berinert/CE1145) in soggetti con deficienza congenita di C1-INH.

Ongoing
3
3
Europe
Powder and solvent for solution for injection, BERINERT*IV FL 500U+FL 10ML
AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE), CSL Behring
Hereditary Angioedema (HAE) angioedema ereditario, Hereditary Angioedema (HAE) angioedema ereditario, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
KONFIDENT, NCT05259917 / 2021-001226-21: A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Completed
3
136
Europe, Canada, Japan, US, RoW
Placebo, KVD900 600 mg, KVD900 300 mg
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
12/23
12/23
OASIS-HAE, NCT05139810 / 2021-002571-19: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Completed
3
91
Europe, Canada, US, RoW
Donidalorsen, Placebo
Ionis Pharmaceuticals, Inc.
Hereditary Angioedema
11/23
11/23
RAPIDe-3, NCT06343779: Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Recruiting
3
120
Europe, Canada, Japan, US, RoW
Deucrictibant, Placebo
Pharvaris Netherlands B.V.
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency
03/26
03/26
2023-001105-31: A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Not yet recruiting
3
20
RoW
TAKHZYRO, TAK-743, SHP643, DX-2930, Solution for injection in vial, Takhzyro
Takeda, Takeda
Hereditary Angioedema (HAE), Angioedema is a long-term and life-threatening disease. It manifests clinically as unpredictable, intermittent attacks of edema of the face, larynx, gastrointestinal tract, limbs and/or genitalia., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
CONE-02, NCT06361537: Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Recruiting
3
124
Europe, US, RoW
OCTA-C1-INH, Placebo
Octapharma
Acute Hereditary Angio Edema
12/26
12/26
NCT05460325 / 2023-001105-31: A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Completed
3
20
RoW
Lanadelumab, SHP643, TAKHZYRO, TAK-743, DX-2930, Lanadelumab Injection
Takeda, Takeda
Hereditary Angioedema (HAE)
11/23
11/23
KONFIDENT-KID, NCT06467084: Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) with HAE Type I or II

Recruiting
3
24
Europe, Canada, Japan, US, RoW
KVD900 75 mg, KVD900 150 mg, KVD900 300 mg
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
08/27
08/27
CHAPTER-3, NCT06669754: Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Recruiting
3
81
Europe, US, RoW
Deucrictibant, Placebo
Pharvaris Netherlands B.V.
Hereditary Angioedema (HAE)
08/26
08/26
HAELO, NCT06634420: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

Recruiting
3
60
Europe, Canada, US, RoW
NTLA-2002, Normal Saline IV Administration
Intellia Therapeutics
Hereditary Angioedema
04/26
09/27
CHAPTER-4, NCT06679881: Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Recruiting
3
130
Europe, RoW
Deucrictibant
Pharvaris Netherlands B.V.
Hereditary Angioedema (HAE)
12/28
12/28
ALPHA-ORBIT, NCT06842823: A Study of Navenibart in Participants with Hereditary Angioedema

Recruiting
3
145
US
navenibart, STAR-0215, Placebo
Astria Therapeutics, Inc.
Hereditary Angioedema (HAE)
03/27
09/27
APeX-P, NCT05453968 / 2021-005932-50: Berotralstat Treatment in Children With Hereditary Angioedema

Active, not recruiting
3
29
Europe, Canada, RoW
Berotralstat, BCX7353, Orladeyo®
BioCryst Pharmaceuticals
Hereditary Angioedema, Pediatric
09/24
02/27
NCT04739059 / 2020-003918-12: Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Active, not recruiting
3
171
Europe, Canada, Japan, US, RoW
CSL312, Factor XIIa inhibitor monoclonal antibody, garadacimab
CSL Behring
Hereditary Angioedema
11/25
11/25
NCT05511922: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Recruiting
3
12
Europe, Canada, Japan, US, RoW
KVD900 600 mg, Drug: KVD900 300 mg
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
06/26
06/26
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Active, not recruiting
3
20
Europe, Canada, US, RoW
CSL312, Garadacimab
CSL Behring
Hereditary Angioedema (HAE)
11/26
11/26
KONFIDENT-S, NCT05505916 / 2021-001176-42: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Active, not recruiting
3
145
Europe, Canada, Japan, US, RoW
KVD900 600 mg, KVD900 300 mg
KalVista Pharmaceuticals, Ltd., KalVista Pharmaceuticals Ltd
Hereditary Angioedema
06/26
06/26
APeX-A, NCT04933721 / 2020-004230-37: Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

Active, not recruiting
3
110
Europe, RoW
berotralstat, Orladeyo
BioCryst Pharmaceuticals
Hereditary Angioedema, HAE
08/26
08/26
NCT05392114 / 2022-000757-93: A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

Recruiting
3
144
Europe, Canada, US, RoW
Donidalorsen, ISIS 721744, IONIS-PKK-LRx
Ionis Pharmaceuticals, Inc.
Hereditary Angioedema
12/26
03/27
2021-006906-58: An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in patients with hereditary angioedema Estudio de extensión de fase II/III para probar la seguridad de la administración a largo plazo de PHA-022121 oral para el tratamiento agudo de los ataques de angioedema en pacientes con angioedema hereditario.

Ongoing
2/3
72
Europe
PHVS416, PHA-022121, Capsule, soft
Pharvaris Netherlands BV, Pharvaris Netherlands BV
Hereditary angioedema attacks caused by Type 1 and 2 C1-Inhibitor Deficiency Ataques de angioedema hereditario causados por la deficiencia del inhibidor C1 tipo 1 y 2, Hereditary angioedema (HAE) is a disorder that results in recurrent attacks of severe swelling El angioedema hereditario (AEH) es un trastorno que provoca ataques recurrentes de inflamación grave, Body processes [G] - Immune system processes [G12]
 
 
RAPIDe-2, NCT05396105: Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema

Enrolling by invitation
2/3
140
Europe, Canada, US, RoW
deucrictibant selected dose, PHVS416, PHA121, PHA-022121
Pharvaris Netherlands B.V.
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema with C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency
06/27
06/27
2015-003923-74: A placebo controlled trial of of three doses of BCX7353 to evaluate the safety and efficacy in the prevention of attacks in patients with HAE

Ongoing
2
24
Europe
BC7353, BCX7353, Capsule, hard
BioCryst Pharmaceuticals Inc, BioCryst Pharmaceutical Inc
Hereditary Angioedema, Hereditary Angioedema, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2018-004136-30: Lanadelumab tested in patients suffering from hereditary angioedema with normal C1-Inhibitor.

Not yet recruiting
2
5
Europe
Lanadelumab, Solution for injection in pre-filled syringe, Takzhyro (Lanadelumab)
Charité - Universitätsmedizin Berlin Klinik für Dermatologie und Allergologie, Shire International GmbH
Lanadelumab in patients with Hereditary angioedema Hereditäres Angioödem, Hereditary angioedema with normal C1-INH is a rare genetic disease which is characterized by self-limiting episodes of marked edema involving the skin, gastrointestinal tract and other organs., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2020-000197-14: An Extension Study of IONIS-PKK-LRx in Participants With Hereditary Angioedema

Not yet recruiting
2
24
Europe
ISIS 721744, Solution for injection
Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc.
Hereditary Angioedema, Genetic disease characterized by the occurrence of transitory and recurrent subcutaneous and/or submucosal edemas resulting in swelling and/or abdominal pain, Body processes [G] - Genetic Phenomena [G05]
 
 
2019-001693-28: Single-arm pharmacokinetic phase 2a study of a single dose intravenous human plasma-derived C1-INH involving 20 HAE type I or type II patients, aged 18 years or older

Not yet recruiting
2
20
Europe
C1 Esterase Inhibitor Human, OCTA-C1-INH, Powder for solution for injection
Octapharma Pharmazeutika Produktionsges.m.b.H., Octapharma Pharmazeutika Produktionsges.m.b.H.
Hereditary angioedema type I and type II, Hereditary angioedema (HAE), Body processes [G] - Immune system processes [G12]
 
 
2018-000605-24: A study to investigate CSL312 in subjects with hereditary angioedema (HAE)

Not yet recruiting
2
50
Europe
Factor XIIa antagonist monoclonal antibody, CSL312, Solution for injection
CSL Behring LLC, CSL Behring LLC
Hereditary angioedema, Hereditary angioedema (HAE) is a condition characterized by painful, recurring attacks of swelling in parts of the body including the face, throat, hands, feet, abdomen., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
2021-000227-13: A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for prophylaxis of angioedema attacks in patients with hereditary angioedema (HAE).

Not yet recruiting
2
30
Europe, RoW
PHVS416, PHA-022121, Capsule, soft
Pharvaris Netherlands BV, Pharvaris Netherlands B.V., Pharvaris Netherlands BV
Hereditary angioedema due to C1-Inhibitor Deficiency (Type I or Type II), Hereditary angioedema (HAE) is a disorder that results in recurrent attacks of severe swelling., Body processes [G] - Immune system processes [G12]
 
 
RAPIDe-1, NCT04618211 / 2020-003445-11: Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

Completed
2
74
Europe, Canada, US, RoW
Deucrictibant, PHA-022121, PHA121, PHVS416, Placebo
Pharvaris Netherlands B.V.
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
09/22
03/23
2021-000136-59: A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.

Not yet recruiting
2
48
Europe, RoW
KVD824 300 mg Modified Release Tablets, [N/A], Modified-release tablet
Kalvista Pharmaceuticals Ltd, KalVista Pharmaceuticals Ltd, Kalvista Pharmaceuticals Ltd
Hereditary Angioedema Type I or II, Hereditary Angioedema is a genetic condition characterised by swelling of tissues. These swellings can occur on any part of the body., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2022-003168-25: Prophylactic treatment with PHA-022121 in patients with acquired angioedema Onderhoudsbehandeling met PHA-022121 voor patiënten met verworven angio-oedeem

Ongoing
2
5
Europe
PHA-022121, Film-coated tablet
Academisch Medisch Centrum, Pharvaris
Acquired angioedema due to C1-inhibitor deficiency Verworven angio-oedeem op basis van een C1-esterase remmer deficiëntie, Acquired angioedema due to C1-inhibitor deficiency Verworven angio-oedeem op basis van een C1-esterase remmer deficiëntie, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2021-000720-36: Acute treatment and prophylaxis for acquired angioedema Aanvals- en onderhoudsbehandeling voor verworven angio-oedeem

Not yet recruiting
2
3
Europe
PHA-022121, Capsule, soft
Academisch Medisch Centrum, Pharvaris
Acquired angioedema due to C1-inhibitor deficiency Verworven angio-oedeem op basis van C1-esterase remmer deficiëntie, Acquired angioedema due to C1-inhibitor deficiency Verworven angio-oedeem op basis van C1-esterase remmer deficiëntie, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
HAE CHAPTER-1, NCT05047185 / 2021-000227-13: Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

Active, not recruiting
2
34
Europe, Canada, US
Deucrictibant low dose, Deucrictibant high dose, Placebo
Pharvaris Netherlands B.V., Pharvaris Netherlands BV
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
06/25
09/25
HAE, NCT06846398: A Phase 2 in Adult Subjects With Hereditary Angioedema

Not yet recruiting
2
24
Europe, US, RoW
BW-20805
Shanghai Argo Biopharmaceutical Co., Ltd.
Hereditary Angioedema (HAE)
06/26
03/28
NCT04307381 / 2020-000197-14: An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

Completed
2
20
Europe, US
Donidalorsen, ISIS 721744, IONIS-PKK-LRx
Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc.
Hereditary Angioedema
01/25
01/25
NCT06007677: A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

Recruiting
2
56
Europe, Canada, US, RoW
STAR-0215
Astria Therapeutics, Inc.
Hereditary Angioedema
03/31
03/31
2021-001693-33: A Study to Evaluate NTLA-2002 in adults with Hereditary Angioedema (HAE)

Not yet recruiting
1/2
55
Europe
NTLA-2002, NTLA-2002, Solution for infusion
Intellia Therapeutics, Inc., Intellia Therapeutics, Inc.
Hereditary Angioedema, Hereditary Angioedema is a genetic condition characterised by swelling of tissues. These swellings can occur on any part of the body., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
2021-003603-18: A Phase 1/2 Study to evaluate the Safety, Tolerability and Efficacy of BMN 331 Gene Therapy in Subjects with Hereditary Angioedema (HAE) Un estudio de fase 1/2 para evaluar la seguridad, tolerabilidad y eficacia de la terapia génica BMN 331 en sujetos con angioedema hereditario (AEH)

Not yet recruiting
1/2
34
Europe
BMN 331, Solution for infusion
BioMarin Pharmaceutical Inc., BioMarin Pharmaceutical Inc.
Hereditary Angioedema (HAE) Angioedema hereditario (AEH), Hereditary Angioedema (HAE) Angioedema hereditario (AEH), Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NTLA-2002, NCT05120830 / 2021-001693-33: in Adults With Hereditary Angioedema (HAE)

Active, not recruiting
1/2
37
Europe, RoW
Biological NTLA-2002, Normal Saline IV Administration
Intellia Therapeutics, Intellia Therapeutics, Inc.
Hereditary Angioedema
04/24
03/26
ALPHA-STAR, NCT05695248: A Study of STAR-0215 in Participants With Hereditary Angioedema

Active, not recruiting
1/2
28
Europe, Canada, US, RoW
STAR-0215
Astria Therapeutics, Inc.
Hereditary Angioedema
09/25
09/25
HAErmony-1, NCT05121376 / 2021-003603-18: A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

Active, not recruiting
1/2
44
Europe, US, RoW
Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331, Dose 4 of BMN 331, Dose 5 of BMN 331, Dose 6 of BMN 331, Dose 7 of BMN 331
BioMarin Pharmaceutical, BioMarin Pharmaceutical Inc.
Hereditary Angioedema, HAE
11/28
11/28
ACTRN12623000689673: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BW-20805 in Healthy Subjects

Recruiting
1
32
 
Argo Biopharma Australia Pty Ltd, Argo Biopharma Australia Pty Ltd
Hereditary angioedema
 
 
NCT05477160: A Study of STAR-0215 in Healthy Adult Participants

Completed
1
41
US
STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV)
Astria Therapeutics, Inc.
Hereditary Angioedema
11/23
11/23
NCT05691361: Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Recruiting
1
53
RoW
ADX-324, siRNA, Placebo, Saline
ADARx Pharmaceuticals, Inc., Avance Clinical Pty Ltd.
Hereditary Angioedema
07/25
01/26
ACTRN12623000736640: An open-label, multiple dose study to compare the single-dose and steady-state pharmacokinetics of a 40 mg PHA-022121 extended-release (XR) tablet administered once daily between healthy Japanese, Chinese, and Caucasian volunteers.

Completed
1
36
 
Pharvaris Netherlands B.V., Pharvaris Netherlands B.V.
Hereditary Angioedema (HAE)
 
 
NCT06415448: Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema

Available
N/A
NA
Donidalorsen, IONIS PKK-LRx, ISIS 721744
Ionis Pharmaceuticals, Inc.
Hereditary Angioedema
 
 
NCT06628713: Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat

Available
N/A
NA
Sebetralstat, KVD900
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
 
 
NCT03828279: Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and II

Recruiting
N/A
220
Europe
functional and antigenic C1 inhibitor, genetic analysis
HAE Global Registry Foundation
Hereditary Angioedema Type I and II
12/19
12/23
NCT01397864: C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

Completed
N/A
181
Europe, RoW
rhC1INH or pdC1INH, Ruconest
Pharming Technologies B.V.
Hereditary Angioedema
10/24
12/24
BESQAOH, NCT04888650: Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema

Completed
N/A
314
Europe
questionnaire
University Hospital, Grenoble
Hereditary Angioedema
01/22
01/22
EMPOWER, NCT03845400: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

Completed
N/A
168
Canada, US
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
10/22
10/22
Angiocoag, NCT02892682: The Role of the Coagulation Pathways in Recurrent Angioedema

Terminated
N/A
96
Europe
BLOOD TEST
University Hospital, Montpellier
Chronic Spotaneous Urticaria, Idiopathic Non Histaminergic Angioderma, Hereditary Angioedema With C1 Inhibitor Deficiency
05/23
05/23
FROSEN, NCT06414252: Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients

Completed
N/A
40
Europe
Istituti Clinici Scientifici Maugeri SpA
Hereditary Angioedema
03/24
03/24
ANS-HAE, NCT06408805: Autonomic Nervous System Profile in Hereditary Angioedema

Completed
N/A
60
Europe
Istituti Clinici Scientifici Maugeri SpA
Hereditary Angioedema
03/24
03/24
NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

No Longer Available
N/A
Europe, Canada, US
Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE), Angioedema
 
 
PRADA, NCT05776784: Status of Dental Care Practices in Patients With Hereditary Angioedema

Recruiting
N/A
800
Europe
dental procedure
University Hospital, Grenoble
Angio Edema Hereditary
07/23
12/23
TAK-743-4008, NCT04955964: A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

Completed
N/A
48
RoW
Takeda
Angioedemas, Hereditary
08/23
08/23
NCT05489640: A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home

Completed
N/A
85
Europe
No Intervention
Takeda
Hereditary Angioedema (HAE)
07/24
07/24
PROSPECT, NCT05578417: A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada

Completed
N/A
60
Canada
No Intervention
Takeda
Hereditary Angioedema (HAE), Angioedema
03/24
06/24
NCT06210698: Angioedema Biomarker Research Study

Not yet recruiting
N/A
600
NA
Venipuncture
Foundation For Rare Disease Research, Institute for Asthma & Allergy, Virant Diagnostics, Inc., MedBio Reference Laboratories, Inc.
Angioedema, Angioedemas, Hereditary, Urticaria, Mastocytosis, ACE Inhibitor-Induced Angioedema, C1 Inhibitor Deficiency, Systemic Mastocytoses, Indolent Systemic Mastocytosis
02/26
02/26
NCT04057131: FIRAZYR General Drug Use-Results Survey (Japan)

Completed
N/A
179
Japan
Firazyr, Icatibant acetate
Shire, Takeda
Hereditary Angioedema (HAE)
07/24
07/24
ITL-2002-CL-999, NCT06262399: Long-Term Follow-Up (LTFU) of Subjects Treated with NTLA 2002

Enrolling by invitation
N/A
100
Europe, RoW
Intellia Therapeutics
Hereditary Angioedema
04/40
04/40
NCT06573723: Institutional Registry of Rare Diseases

Recruiting
N/A
380
RoW
Hospital Italiano de Buenos Aires
Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, Cushing Syndrome
12/34
12/34
NCT06346899: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

Recruiting
N/A
130
RoW
No intervention
Takeda
Hereditary Angioedema (HAE)
08/25
08/25
ENABLE, NCT04130191: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

Completed
N/A
140
Europe, RoW
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
09/24
09/24
SPEAKUP, NCT06587464: A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People

Completed
N/A
19
RoW
No Intervention
Takeda
Hereditary Angioedema (HAE)
12/24
12/24
HAE-SAFE, NCT06811467: Suicide Ideation in Hereditary Angioedema

Not yet recruiting
N/A
100
NA
Ivan Cherrez Ojeda
Hereditary Angioedema (HAE), Suicidal Ideation, Cardiovascular Risk
08/25
09/25
ECRINS, NCT06806618: HAE Burden and Crisis Management

Recruiting
N/A
300
Europe
University Hospital, Grenoble
Hereditary Angioedema (HAE)
04/25
04/25
NCT05509569: A Survey of Icatibant in Pediatric Participants with Hereditary Angioedema

Active, not recruiting
N/A
32
RoW
Icatibant, FIRAZYR Subcutaneous Injection 30mg Syringe
Takeda
Hereditary Angioedema (HAE)
10/25
10/25
NCT05469789: A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)

Active, not recruiting
N/A
50
Europe
No Intervention
Takeda
Hereditary Angioedema (HAE)
12/26
12/26
ChiCTR2500099926: Phase I clinical study on the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of recombinant human C1 esterase inhibitor for injection in patients with hereditary angioedema

Not yet recruiting
N/A
18
 
Complete intravenous injection of 25 IU/kg within 2 minutes; Complete intravenous injection of 50 IU/kg within 5 minutes; Complete intravenous injection of 100 IU/kg within 10 minutes
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Chengdu Institute of Biological Products Co., Ltd, Self raised by enterprises
Hereditary angioedema
 
 
CHOPIN, NCT05147181: A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

Active, not recruiting
N/A
48
Europe
Takeda
Hereditary Angioedema (HAE)
03/26
03/26
GENOMAEH_01, NCT05833620: Identification and Characterization of Genetic Variants in Hereditary Angioedema

Not yet recruiting
N/A
200
Europe
Hospital Universitari Vall d'Hebron Research Institute, Hospital Universitario La Paz
Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
03/26
03/27
NCT05397431: A Survey of Lanadelumab in Participants with Hereditary Angioedema

Recruiting
N/A
100
Japan
Lanadelumab, SHP643 (TAK-743), TAKHZYRO
Takeda
Hereditary Angioedema (HAE)
01/26
01/26
NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Completed
N/A
1761
Europe, RoW
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
05/24
05/24
NAREG, NCT05904301: Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases

Recruiting
N/A
800
RoW
Usual medical management of patients, additional blood and stool samples for biobanking
Santé Arménie French-Armenian Research Center
Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis, Takayasu Arteritis, Giant Cell Arteritis, Sjogren's Syndrome, Rheumatoid Arthritis, Hereditary and Acquired Angioedema, Primary Antiphospholipid Syndrome, Celiac Disease
06/28
06/28
ACTRN12621000473864: The influence of stress and lifestyle in hereditary angioedema

Completed
N/A
32
 
University of Auckland, Auckland City Hospital
Hereditary angioedema
 
 

Download Options